Background and Objectives Five-tumour necrosis factor (TNF)-blockers (infliximab,
etanercept, adalimumab, certolizumab pegol and golimumab) are available for treatment of …

Patients with rheumatoid arthritis (RA) have a greater risk of developing both Hodgkin
lymphoma (HL) and non‐HL than the general population. Non‐Hodgkin lymphoma is more …

Context Concerns exist regarding the potential development of malignancies in patients with
rheumatoid arthritis (RA) who are receiving biologic response modifiers (BRMs). Objective …

Objective The study objective was to evaluate and update the safety data from randomized
controlled trials of tumor necrosis factor inhibitors in patients treated for rheumatoid arthritis …

Objective. To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors
adalimumab, etanercept, and infliximab among patients with longstanding rheumatoid …

Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are
immune-mediated conditions that share an inflammatory mechanism fuelled by excessive …

The aim of the present study was to conduct a meta-analysis of the effectiveness of
tofacitinib, a novel oral Janus kinase inhibitor, recently approved for the treatment of active …

Objective Treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic
drugs (DMARDs), either synthetic (sDMARDs) or biologic agents (bDMARDs) has …

Objective To evaluate whether disease activity-guided tapering of biologics compared to
continuation as usual care enables a substantial dose reduction while disease activity …

Introduction Infliximab (IFX) was the first anti-tumor necrosis factor (TNFα) antibody to be
used in the treatment of severe chronic inflammatory diseases, such as Crohn's disease and …